Real-World Treatment Patterns and Survival Outcomes of Advanced Non-Small Cell Lung Cancer Medicare Patients
Author(s)
Olayiwola Popoola, PhD1, Rima Tawk, PhD1, Sandra Suther, PhD2, Matthew Dutton, PhD2, Karam Diaby, BSc, MSc, PhD3, Askal Ayalew Ali, BA, MA, PhD4.
1Florida A&M University, Tallahassee, FL, USA, 2Florida A&M Universi, Tallahassee, FL, USA, 3Otsuka Pharmaceutical Inc, Princeton, NJ, USA, 4Associate Professor, Florida A & M University, Tallahassee, FL, USA.
1Florida A&M University, Tallahassee, FL, USA, 2Florida A&M Universi, Tallahassee, FL, USA, 3Otsuka Pharmaceutical Inc, Princeton, NJ, USA, 4Associate Professor, Florida A & M University, Tallahassee, FL, USA.
OBJECTIVES: To describe the real-world treatment pattern and overall survival (OS) among advanced non-small cell lung cancer (NSCLC) Medicare patients.
METHODS: We retrospectively analyzed data of NSCLC patients identified using the Surveillance, Epidemiology, and End Results (SEER) and Medicare Program dataset who received systemic therapy after diagnosis between 2015 and 2020. Patient characteristics, first-line (1L) regimen duration, OS, and factors associated with survival time were analyzed.
RESULTS: A total of 5890 NSCLC patients were included in the study, of which 49.3% initiated 1L chemotherapy, 28.5% initiated 1L immunotherapy, 14.1% initiated targeted therapy, and 8.1% initiated a bevacizumab containing regimen. The median OS from 1L initiation was 19.3 (95% CI: 17.2 - 21.2) months for 1L targeted therapy patients, 10.4 (95% CI: 9.3 - 11.4) months for 1L immunotherapy patients, 9.2 (95% CI: 8.7 - 10.0) months for 1L chemotherapy patients and 11.0 (95% CI: 9.4 - 12.4) months for 1L bevacizumab containing regimen patients.
CONCLUSIONS: This real-world study found that 1L targeted therapy had longer OS compared to other systemic therapies.
METHODS: We retrospectively analyzed data of NSCLC patients identified using the Surveillance, Epidemiology, and End Results (SEER) and Medicare Program dataset who received systemic therapy after diagnosis between 2015 and 2020. Patient characteristics, first-line (1L) regimen duration, OS, and factors associated with survival time were analyzed.
RESULTS: A total of 5890 NSCLC patients were included in the study, of which 49.3% initiated 1L chemotherapy, 28.5% initiated 1L immunotherapy, 14.1% initiated targeted therapy, and 8.1% initiated a bevacizumab containing regimen. The median OS from 1L initiation was 19.3 (95% CI: 17.2 - 21.2) months for 1L targeted therapy patients, 10.4 (95% CI: 9.3 - 11.4) months for 1L immunotherapy patients, 9.2 (95% CI: 8.7 - 10.0) months for 1L chemotherapy patients and 11.0 (95% CI: 9.4 - 12.4) months for 1L bevacizumab containing regimen patients.
CONCLUSIONS: This real-world study found that 1L targeted therapy had longer OS compared to other systemic therapies.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
CO130
Topic
Clinical Outcomes
Topic Subcategory
Clinical Outcomes Assessment
Disease
SDC: Oncology